Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.

Antimicrobial agents and chemotherapy - 1 Sept 2004

Tenney D J, Levine S M, Rose R E, Walsh A W, Weinheimer S P, Discotto L, Plym M, Pokornowski K, Yu C F, Angus P, Ayres A, Bartholomeusz A, Sievert W, Thompson G, Warner N, Locarnini S, Colonno R J

Abstract excerpt

Entecavir (ETV) exhibits potent antiviral activity in patients chronically infected with wild-type or lamivudine (3TC)-resistant (3TC(r)) hepatitis B virus (HBV). Among the patients treated in phase II ETV clinical trials, two patients for whom previous therapies had failed exhibited virologic br...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Capsid Proteins
Share to DNA-Directed DNA Polymerase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Guanine

Share to Hepatitis B

Share to Lamivudine

Share to Reverse Transcriptase Inhibitors

Share to RNA-Directed DNA Polymerase

Share to Treatment Failure

Source

Open in PubMed Open full text

Identifiers

PMID: 15328117
DOI: 10.1128/AAC.48.9.3498-3507.2004
PMCID: PMC514758

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-15328117-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.PMID 15328117Read ↗

Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.Semantic proximity Read ↗

Entecavir resistance is rare in nucleoside naïve patients with hepatitis BSemantic proximity Read ↗

Characterization of novel entecavir resistance mutations.Semantic proximity Read ↗

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #Semantic proximity Read ↗

Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response.Semantic proximity Read ↗

Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistanceSemantic proximity Read ↗

Successful treatment of an entecavir-resistant hepatitis B virus variant.Semantic proximity Read ↗

Adefovir and lamivudine combination therapy in patients with entecavir-resistant chronic hepatitis B: antiviral responses and evolution of mutations.Semantic proximity Read ↗

Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistanceSemantic proximity Read ↗

Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience.Semantic proximity Read ↗

Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.Semantic proximity Read ↗

Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.